DS
Therapeutic Areas
Zydus Lifesciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Saroglitazar (Lipaglyn/Magdrop) | Non-alcoholic steatohepatitis (NASH) | Phase 3 |
| Twinrab (Docaravimab + Miromavimab) | Rabies Post-Exposure Prophylaxis | Marketed |
| BEIZRAY (Albumin Solubilized Docetaxel) | Oncology (Solid Tumors) | Pre-registration |
| Biosimilar Pipeline (e.g., Bevacizumab, Trastuzumab) | Oncology, Autoimmune Diseases | Phase 3 / Registration |
| NCE Pipeline Assets | Cardio-Metabolic, Inflammation, Oncology, Rare Diseases | Preclinical to Phase 2 |